Equivalent disease free and overall survival in lymphoma patients treated with either myeloablative (MA) or non-myeloablative (NMA) conditioning and allogeneic stem cell transplant (SCT)

Abstract

We compared outcomes of 141 consecutive patients who received allogeneic SCT between 1997 and 2004 with either MA or NMA conditioning to treat non-Hodgkin (MA= 62; NMA = 53) or Hodgkin (MA = 3; NMA = 23) lymphoma. NMA patients were older [MA: 42 years (4–58); NMA: 48 years (19–66)] and more recently transplanted [1997–2000: MA = 31; NMA = 10; 2001–2004: MA = 34; NMA = 66]. Cord blood was used more frequently in the NMA cohort [MA: 6 (9%); NMA: 33 (43%)]. NMA patients had more advanced disease with 57 (75%) in second or greater partial remission (PR) versus 37 (57%) MA patients.